Linezolid: First of a new drug class for Gram-positive infections

被引：0

作者：

Atanaskova N. ^{[1
]}

Keshamouni V.G. ^{[1
]}

Krueger J.S. ^{[1
]}

Schwartz J.A. ^{[2
]}

Miller F. ^{[1
]}

Reddy K.B. ^{[1
]}

机构：

[1] Department of Pathology, Wayne State University School of Medicine, Detroit, MI 48201

[2] Department of Physiology, Wayne State University School of Medicine, Detroit, MI 48201

来源：

Drugs & Therapy Perspectives | 2001年 / 17卷 / 9期

关键词：

Adis International Limited; Linezolid; Soft Tissue Infection; Neisseria Gonorrhoeae; Chlamydial Infection;

D O I：

10.2165/00042310-200117090-00001

中图分类号：

学科分类号：

摘要：

Linezolid is an oxazolidinone-type antibacterial agent which inhibits bacterial protein synthesis by specifically binding to the 50S ribosomal subunit. Linezolid is active against Gram-positive organisms and certain anaerobes, and has shown some bactericidal activity. Methicillin-resistant staphylococci, penicillin-resistant Streptococcus pneumoniae and vancomycin-resistant Enterococcus faecalis and E. faecium are susceptible to linezolid. This agent is effective in patients with skin and soft tissue infections, community-acquired and nosocomial pneumonia, and bacteraemia, and has similar efficacy to that of other standard treatments. Resistance to linezolid has been reported in a small number of patients infected with E. faecium. Linezolid is generally well tolerated and most events (mainly GI-related) are of mild to moderate intensity, resolve during continuous linezolid treatment and are not dose-related. Linezolid is an important new drug which is likely to be of use in the treatment of serious or complicated infections due to potentially resistant Gram-positive organisms.

引用

页码：1 / 6

页数：5